The investigation of JAK2 V617F point mutation in myeloproliferative disorders by allele-specific polymerase chain reaction in combination with sequence analysis

National Medical Journal of China

Volumn 87, Issue 30, 2007, Pages 2109-2112

  Zhang, Su Jiang ^a   Li, Wei Da ^a   Song, Jun Hong ^a   Xu, Wei ^a   Qiu, Hong Xia ^a   Li, Jian Yong ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Alleles; JAK2; Mutation; Myeloproliferative disorders; Polymerase chain reaction

Indexed keywords

BCR ABL PROTEIN; GENOMIC DNA; HEMOGLOBIN; JANUS KINASE 2;

ADULT; AGED; ALLELE; ARTICLE; CANCER CLASSIFICATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; HEMATOCRIT; HUMAN; HUMAN CELL; HYPEREOSINOPHILIC SYNDROME; IDIOPATHIC DISEASE; MAJOR CLINICAL STUDY; MALE; MOLECULAR GENETICS; MUTATIONAL ANALYSIS; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDER; NEUTROPHIL COUNT; PERIPHERAL BLOOD MONONUCLEAR CELL; POINT MUTATION; POLYCYTHEMIA VERA; POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; THROMBOCYTOPENIA;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; BASE SEQUENCE; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; MUTATION, MISSENSE; MYELOPROLIFERATIVE DISORDERS; POINT MUTATION; POLYMERASE CHAIN REACTION;

EID: 35648941724     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood, 2002, 100: 2292-2302.
2. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet, 2005, 365:1054-1061.
3. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vere. Nature, 2005, 434: 1144-1148.
4. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med, 2005, 352: 1779-1790.
5. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell, 2005, 7: 387-397.
6. Zhao R, Xing S, Li Z, et al. Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem, 2005, 280: 22788-22792.
7. Chinese source.
8. Chinese source.
9. Jones AV, Kreil S, Zoi K, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood, 2005, 106: 2162-2168.
10. Jason S, Rawlings, Kristin M, et al. The JAK/STAT signaling pathway. J Cell Sci, 2004, 117: 1281-1283.
11. Kaushansky K. On the molecular origins of the chronic myeloproliferative disorders: it all makes sense. Blood, 2005, 105: 4187-4190.
12. Campbell PJ, Scott LM, Buck G, et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet, 2005, 366: 1945-1953.